



For Immediate Release

August 4, 2017

VALENS GROWORKS ANNOUNCES AGM RESULTS, NEW APPOINTMENT

Vancouver, B.C., August 4, 2017 – Valens GroWorks Corp. (CSE: VGW) (the “Company” or “Valens”), a vertically integrated provider of cannabis products, is pleased to announce the voting results from the Company’s Annual General Meeting (“AGM”), and subsequent board meeting, held in Vancouver, British Columbia on August 4, 2017.

A total of 47,505,896 common shares were represented at the AGM, representing 84.48% of the votes attached to all outstanding common shares as at the record date. All of the matters submitted to the shareholders for approval as set out in the Company’s notice of meeting and management information circular, dated June 30, 2017, were approved by the requisite majority of votes cast at the AGM. Shareholders voted in favour of setting the number of directors at six (6) and elected all incumbent directors.

Immediately following the AGM, the board of directors elected Mr. Saul Katz, recently appointed as the Company’s President, as a seventh member of the board, as well as its Executive Chairman.

About Valens GroWorks Corp.

Valens GroWorks Corp is a CSE-listed company with an aggressive buildout strategy in progress. The Company seeks to capture a broad spectrum of clinical trial and R&D clients, medical marijuana users, as well as adult recreational users once legalized, in pursuit of its ambitious seed-to-sale and farm-to-pharma objectives. The Company also provides management, consulting, testing and support services to domestic and international licensees, as well as financing and managing buildouts of fully-licensed 3rd party operations.

The Company has two wholly-owned subsidiaries based in the Okanagan Valley of British Columbia: 1) Valens Agritech Ltd. (“VAL”) which holds a Controlled Drugs and Substances Dealers Licence at its state-of-the-art production facility in Kelowna, British Columbia, and 2) Supra THC Services Inc. (“Supra”), a Health Canada licensed cannabis testing lab providing sector-leading analytical and proprietary services to Licensed Producers and ACMPR patients.

**On behalf of the Board of Directors,
VALENS GROWORKS CORP.**

(signed) “Tyler Robson”
Chief Executive Officer

For further information, please contact:

Greg Patchell
Telephone: +1.250.860.8634

Notice regarding Forward Looking Statements

This news release contains certain “forward-looking statements” within the meaning of such statements under applicable securities law. Forward-looking statements are frequently characterized by words such as “anticipates”,

"plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Corporation is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.

The CSE or other regulatory authority has not reviewed, approved or disapproved the contents of this press release. We seek Safe Harbour.